TransMedics Group (NASDAQ:TMDX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of TransMedics Group (NASDAQ:TMDX) from a hold rating to a buy rating in a research report sent to investors on Saturday.

A number of other equities analysts also recently commented on TMDX. Needham & Company LLC upped their target price on TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a report on Monday, December 8th. Morgan Stanley upped their price objective on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Piper Sandler reaffirmed an “overweight” rating on shares of TransMedics Group in a research report on Monday, December 22nd. Finally, Canaccord Genuity Group boosted their price target on shares of TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, TransMedics Group presently has an average rating of “Moderate Buy” and an average price target of $144.25.

TransMedics Group Stock Up 1.0%

Shares of NASDAQ:TMDX opened at $129.84 on Friday. The stock’s 50-day moving average is $132.18 and its 200 day moving average is $125.62. The company has a market cap of $4.44 billion, a PE ratio of 52.57 and a beta of 2.06. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13. TransMedics Group has a 1 year low of $62.07 and a 1 year high of $156.00.

Insider Transactions at TransMedics Group

In other TransMedics Group news, Director David Weill sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total transaction of $693,200.00. Following the completion of the transaction, the director owned 12,134 shares of the company’s stock, valued at approximately $1,682,257.76. This trade represents a 29.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Anil P. Ranganath sold 3,000 shares of TransMedics Group stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total transaction of $435,660.00. Following the transaction, the insider owned 13,955 shares of the company’s stock, valued at $2,026,545.10. The trade was a 17.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 8,920 shares of company stock valued at $1,257,310 in the last three months. 7.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TMDX. Panagora Asset Management Inc. boosted its holdings in TransMedics Group by 33.7% in the fourth quarter. Panagora Asset Management Inc. now owns 102,025 shares of the company’s stock worth $12,411,000 after acquiring an additional 25,725 shares in the last quarter. MML Investors Services LLC raised its position in shares of TransMedics Group by 3.6% in the 4th quarter. MML Investors Services LLC now owns 11,934 shares of the company’s stock worth $1,452,000 after purchasing an additional 419 shares during the last quarter. Mariner LLC boosted its stake in TransMedics Group by 4.7% in the 4th quarter. Mariner LLC now owns 9,022 shares of the company’s stock worth $1,098,000 after purchasing an additional 405 shares in the last quarter. Next Century Growth Investors LLC grew its position in TransMedics Group by 81.2% during the 4th quarter. Next Century Growth Investors LLC now owns 98,468 shares of the company’s stock valued at $11,979,000 after purchasing an additional 44,118 shares during the last quarter. Finally, Entropy Technologies LP bought a new stake in TransMedics Group during the 4th quarter valued at about $455,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.